Passage Bio Inc (PASG) ニュース

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic...

Form 8-K - Current report

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Interim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02...

Passage Bio Welcomes Tom Kassberg to Board of Directors

PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic...

Form 8-K - Current report

Form 8-K - Current report

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data...

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic...

Form 8-K - Current report

Form 8-K - Current report

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis...